Zacks Research Issues Optimistic Forecast for IQVIA Earnings

IQVIA Holdings Inc. (NYSE:IQV) – Equities researchers at Zacks Research raised their Q4 2025 earnings per share (EPS) estimates for IQVIA in a research note issued to investors on Tuesday, February 25th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $3.05 per share for the quarter, up from their previous forecast of $2.86. The consensus estimate for IQVIA’s current full-year earnings is $10.84 per share. Zacks Research also issued estimates for IQVIA’s Q3 2026 earnings at $3.24 EPS.

Other analysts also recently issued reports about the company. Bank of America reduced their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. TD Cowen cut their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Robert W. Baird reduced their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. Finally, William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Trading Down 2.4 %

Shares of IQVIA stock opened at $186.40 on Thursday. IQVIA has a 12-month low of $184.66 and a 12-month high of $261.73. The stock has a market cap of $32.82 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 1.99 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a fifty day simple moving average of $199.30 and a 200-day simple moving average of $215.26.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%.

Insider Activity

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several hedge funds have recently bought and sold shares of IQV. Norges Bank bought a new position in IQVIA in the 4th quarter worth $336,041,000. Raymond James Financial Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth $236,120,000. American Century Companies Inc. increased its position in shares of IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock valued at $222,987,000 after buying an additional 905,960 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after buying an additional 902,226 shares during the period. Finally, FMR LLC boosted its holdings in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.